Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes
- PMID: 34086529
- DOI: 10.1080/08897077.2021.1931633
Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes
Abstract
Background: Our rural health system sought to (1) increase the number of primary care clinicians waivered to prescribe buprenorphine for treatment of opioid use disorder (OUD) and (2) consequently increase the number of our patients receiving this treatment. Methods: We used the Project for Extension for Community Health Outcomes (ECHO) tele-education model as an implementation strategy. We examined the number of clinicians newly waivered, the number of patients treated with buprenorphine, the relationship between clinician engagement with ECHO training and rates of buprenorphine prescribing, and treatment retention at 180 days. Results: The number of clinicians with a waiver and number of patients treated increased during and after ECHO training. There was a moderate correlation between the number of ECHO sessions attended by a clinician and number of their buprenorphine prescriptions (r = 0.50, p = 0.01). The 180-day retention rate was 80.7%. Conclusions: Project ECHO was highly effective for increasing access to this evidence-based treatment. The high retention rate in this rural context indicates that most patients are increasing their likelihood of favorable outcomes.
Keywords: Opioid use disorder; Project ECHO; buprenorphine; medication assisted treatment; medications for opioid use disorder; primary care; treatment retention rate.
Similar articles
-
Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder.JAMA Health Forum. 2022 Nov 4;3(11):e224149. doi: 10.1001/jamahealthforum.2022.4149. JAMA Health Forum. 2022. PMID: 36399352 Free PMC article.
-
Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.J Rural Health. 2022 Jan;38(1):87-92. doi: 10.1111/jrh.12569. Epub 2021 Mar 18. J Rural Health. 2022. PMID: 33733547
-
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z. Addict Sci Clin Pract. 2021. PMID: 33676577 Free PMC article. Review.
-
Full agonist opioid prescribing by primary care clinicians after buprenorphine training.Subst Abus. 2022;43(1):69-75. doi: 10.1080/08897077.2020.1736709. Epub 2020 Mar 9. Subst Abus. 2022. PMID: 32150525
-
Medications for management of opioid use disorder.Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105. Am J Health Syst Pharm. 2019. PMID: 31361869 Review.
Cited by
-
Project ECHO for Diabetes Improves Primary Care Providers' Comfort With and Use of Diabetes Medications and Technology.Diabetes Spectr. 2024 Spring;37(2):160-164. doi: 10.2337/ds23-0050. Epub 2024 Jan 26. Diabetes Spectr. 2024. PMID: 38756423 No abstract available.
-
Project ECHO®: a global cross-sectional examination of implementation success.BMC Health Serv Res. 2024 May 3;24(1):583. doi: 10.1186/s12913-024-10920-5. BMC Health Serv Res. 2024. PMID: 38702685 Free PMC article.
-
Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.Harm Reduct J. 2023 Dec 21;20(1):180. doi: 10.1186/s12954-023-00918-3. Harm Reduct J. 2023. PMID: 38129903 Free PMC article.
-
Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.J Subst Use Addict Treat. 2024 Jan;156:209212. doi: 10.1016/j.josat.2023.209212. Epub 2023 Nov 5. J Subst Use Addict Treat. 2024. PMID: 37935350
-
Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.Drug Alcohol Depend. 2023 Nov 1;252:110963. doi: 10.1016/j.drugalcdep.2023.110963. Epub 2023 Sep 14. Drug Alcohol Depend. 2023. PMID: 37748421
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical